News
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Secures an Additional $3 Million Payment from Future Pak for Mytesi and Canalevia-CA1
Jaguar Health, Inc. receives $16M non-dilutive capital from U.S. license agreement with Future Pak for crofelemer drugs. Strategy focuses on rare-disease intestinal failure indications -
-
-
COMMUNIQUÉ DE PRESSE
Reminder: Today, March 2, 2026, is the Record Date for Jaguar Health's Special One-time Stock Dividend
Jaguar Health issues a Special Stock Dividend to provide dilution protection to shareholders as part of debt restructuring efforts. Preferred Stock payment date on March 4, 2026 -
-
-
-